Saprolegnia inhibitor as well as preparation method and application thereof

The water mold inhibitor prepared by combining Agaricus bisporis, Agrobacterium nitus Z01 and Lactobacillus paracasei LY02 has solved the problem of strong pathogenicity in freshwater aquaculture, and achieved effective inhibition of water mold and Prevent, avoid the problem of drug disabilities and ensure the health and safety of aquatic animals.

CN119054708AActive Publication Date: 2024-12-03YANGTZE RIVER FISHERIES RES INST CHINESE ACAD OF FISHERY SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411274522.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-12-03
Estimated Expiration
2044-09-12

AI Technical Summary

Technical Problem

Aquamillaria is widely present in freshwater aquaculture, especially in low temperature seasons, with significant pathogenicity. Traditional chemical drugs such as malachite green have been banned due to toxicity and environmental residue problems, resulting in the lack of effective and safe aquamillar control strategies.

Method used

A water mold inhibitor, including Agaricus bisporus, Agaricus nitus Z01 and Lactobacillus paracasei LY02, was prepared by specific culture methods, combined with ergothionein, to form a water mold inhibitor, which is used to inhibit the vitality and reproduction of water mold. ability.

Benefits of technology

Effectively prevent and inhibit water mold disease, enrich the types of bio-drug bacteria, broaden the application of water mold disease prevention and control in aquaculture, avoid the problem of drug residues, and is harmless to the health, safety and harmless to the health, safety and safety of grass carp.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119054708A_ABST
    Figure CN119054708A_ABST
Patent Text Reader

Abstract

The invention discloses a water mildew inhibitor as well as a preparation method and application thereof, and the water mildew inhibitor comprises agaricus bisporus polysaccharide, Epicoccum nigrum Z01, Lactobacillus paracasei LY02 and ergothioneine, and is characterized in that the water mildew inhibitor is prepared from the following raw materials: Agaricus bisporus polysaccharide, Epicoccum nigrum Z01, Lactobacillus paracasei LY02 and ergothioneine; the preservation number of the epicoccum nigrum Z01 is CCTCC (China Center For Type Culture Collection) NO: M2024967. The concentration of agaricus bisporus polysaccharide in the water mildew inhibitor is 100-500 mg / L, and the spore concentration of epicoccum nigrum Z01 is (1.0-8.0) * 10 < 8 > / mL. The concentration of the lactobacillus paracasei LY02 in the water mildew inhibitor is (1.0-5.0) * 10 < 9 > CFU / mL. The concentration of ergothioneine in the water mildew inhibitor is 300 to 500 [mu] mol / L. The feed additive can effectively inhibit infection of saprolegnia to aquatic animals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microbial preparations, and in particular to a saprolegnia inhibitor and a preparation method and application thereof. Background Art

[0002] In freshwater aquaculture, Saprolegnia, as a widespread fungal disease, has long posed a serious threat to the health of aquatic animals, especially in low-temperature seasons, where its pathogenicity is particularly significant. Saprolegnia can infect all life stages of aquatic animals and has no strict selectivity for hosts, which greatly increases the difficulty of prevention and control. During the infection process, Saprolegnia can inhibit the host's defense response through its unique effector protein transport mechanism, leading to epidermal cell damage and tissue decay, which in turn causes aquatic animals to swim slowly, weaken their vitality, and even die, causing huge economic losses to the aquaculture industry.

[0003] Grass carp (Ctenopharyngodon idella), as one of the traditional freshwater farmed fish in China, is farmed on a large scale in China due to its wide adaptability and economic value. However, grass carp also faces the serious challenge of Saprolegniasis, especially under environmental stress and decreased immunity, it is very susceptible to Saprolegniasis. The occurrence of Saprolegniasis not only affects the growth performance and quality of grass carp, but also may cause a large number of deaths of individuals at different growth stages, directly threatening the sustainable development of the aquaculture industry.

[0004] With the increasing awareness of environmental protection and the improvement of food safety standards, traditional chemical drugs such as malachite green have been gradually banned or restricted due to their potential toxicity and environmental residue problems. This change has prompted researchers to turn to safer and more environmentally friendly biological control methods to explore alternative strategies for controlling saprolegnia. In recent years, more and more studies have shown that there are a variety of microorganisms with antagonistic effects on saprolegnia in nature, such as Serratia marcescens, Aeromonas, Pseudomonas, Bacillus and Actinomycetes. These microorganisms can not only effectively inhibit the growth of saprolegnia, but also have the advantages of no residue and environmental friendliness, showing great application potential. Summary of the invention

[0005] The object of the present invention is to provide a saprolegnia inhibitor and a preparation method and application thereof, which are used to inhibit the infection of saprolegnia to aquatic animals.

[0006] The purpose of the present invention is achieved by the following technical solutions:

[0007] In a first aspect, the present invention provides a Saprolegnia inhibitor, comprising: Agaricus bisporus polysaccharide and Epicoccumnigrum Z01;

[0008] The deposit number of Echinococcus nigromaculata Z01 is CCTCCNO: M2024967.

[0009] Furthermore, the concentration of Agaricus bisporus polysaccharide in the Saprolegnia inhibitor is 100-500 mg / L, and the concentration of spores of Echinococcus nigromaculata Z01 is 1.0-8.0×10 8 Pieces / mL.

[0010] Furthermore, the saprolegnia inhibitor also includes:

[0011] Lactobacillus paracasei LY02, wherein the concentration of Lactobacillus paracasei LY02 in the saprolegnia inhibitor is 1.0-5.0×10 9 CFU / mL.

[0012] Furthermore, the saprolegnia inhibitor also includes:

[0013] Ergothioneine, wherein the concentration of ergothioneine in the saprolegnia inhibitor is 300-500 μmol / L.

[0014] In a second aspect, the present invention provides a method for preparing a saprolegnia inhibitor, comprising the following steps:

[0015] The black cloacae Z01 was inoculated into a potato dextrose broth medium, and cultured in a shaker at 175 rpm and 25°C for 5 days, and then filtered through three layers of sterile gauze to obtain a filtrate as the black cloacae Z01 culture medium; the black cloacae Z01 culture medium;

[0016] Agaricus bisporus polysaccharide is added into the culture solution of Echinococcus nigrosporus Z01, and the mixture is evenly mixed to obtain a Saprolegnia inhibitor.

[0017] Furthermore, the preparation method of the saprolegnia inhibitor further comprises:

[0018] Inoculate Lactobacillus paracasei LY02 into a liquid culture medium of Lactobacillus delbrueckii, place the culture medium in a shaking table, and filter the culture medium with three layers of sterile gauze to obtain a culture medium of Lactobacillus paracasei LY02;

[0019] The culture solution of Lactobacillus paracasei LY02 was added to the culture solution of Echinococcus nigromatis Z01, and the mixture was evenly mixed to obtain a Saprolegnia inhibitor.

[0020] Furthermore, the method for preparing the saprolegnia inhibitor further comprises: adding ergothioneine to the culture solution of Echinococcus nigromatis Z01 and mixing the mixture evenly to obtain the saprolegnia inhibitor.

[0021] Furthermore, the OD600 of the culture solution of Echinococcus nigromaculata Z01 is 1.2-1.5.

[0022] Furthermore, the OD600 of the Lactobacillus paracasei LY02 culture solution is 1.2-1.5.

[0023] In a third aspect, the present invention further provides a use of a Saprolegnia inhibitor in treating or preventing fungal infection, wherein the Saprolegnia inhibitor is the above-mentioned Saprolegnia inhibitor.

[0024] Compared with the prior art, the beneficial effects of the present invention include at least:

[0025] The saprolegnia inhibitor of the present invention can effectively inhibit the vitality and reproductive capacity of fungi, and in particular can prevent saprolegniasis caused by saprolegnia pathogenic bacteria. It can be seen that the present invention not only enriches the types of biocontrol bacteria, but also broadens the application of biocontrol bacteria in the field of saprolegniasis prevention and control in aquaculture. Furthermore, the present invention not only provides a new solution for the prevention and control of saprolegniasis in freshwater aquaculture animals, but also effectively avoids the problem of drug residues. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 : is a curve chart of the Saprolegnia infection rate of each group of grass carp in the embodiment of the present invention.

[0027] Figure 2 : is a comparison diagram of liver tissue sections of each group of grass carp according to the embodiment of the present invention.

[0028] Figure 3 : is a comparison diagram of the intestinal tissue sections of each group of grass carp according to the embodiments of the present invention.

[0029] Figure 4 : is a comparison diagram of muscle tissue sections of each group of grass carp according to the embodiment of the present invention. DETAILED DESCRIPTION

[0030] Example embodiments will now be described more fully with reference to the accompanying drawings. However, example embodiments can be implemented in a variety of forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided to make the present invention more comprehensive and complete and to fully convey the concepts of example embodiments to those skilled in the art. The same reference numerals in the figures represent the same or similar structures, and thus their repeated description will be omitted.

[0031] The words expressing position and direction described in the present invention are all explained by taking the accompanying drawings as examples, but they can be changed as needed, and all changes are included in the protection scope of the present invention.

[0032] Introduction to the strains, drugs and instruments involved in this application:

[0033] Potato dextrose agar medium was purchased from Qingdao Hi-Tech Industrial Park Haibo Biotechnology Co., Ltd.

[0034] Potato dextrose broth medium was purchased from Qingdao Hi-Tech Industrial Park Haibo Biotechnology Co., Ltd.

[0035] Lactobacillus delbrueckii solid culture medium, Qingdao Haibo Biotechnology Co., Ltd.

[0036] Lactobacillus delbrueckii liquid culture medium, Qingdao Haibo Biotechnology Co., Ltd.

[0037] The bacterial genomic DNA extraction kit (DP302) was purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.

[0038] Agaricus bisporus polysaccharide was purchased from Xi'an Huilin Biotechnology Co., Ltd.

[0039] Ergothioneine was purchased from Guangdong Mingcheng Biotechnology Co., Ltd.

[0040] Giemsa staining solution was purchased from Beijing Solebow Technology Co., Ltd.

[0041] Sterile gauze is gauze that has been sterilized at high temperature. The gauze was purchased from Caoxian Hualu Sanitary Materials Co., Ltd. The production batch number is 23082501 and the specification model is 21s x 32s.

[0042] The Ezup column-based fungal genomic DNA extraction kit was purchased from Sangon Biotech (Shanghai) Engineering Co., Ltd.

[0043] Epicoccumnigrum Z01 was collected from the laboratory of the Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, and preserved in the China Type Culture Collection, Luojia Mountain, Bayi Road, Wuchang District, Wuhan City, Hubei Province, with the preservation number CCTCCNO: M2024967 and the preservation date May 16, 2024.

[0044] The present invention uses Giemsa staining to observe the morphology of blood cells, including:

[0045] Use soap or washing powder to boil the slide for 20 minutes, then rinse it repeatedly with hot water and tap water, and finally rinse it with distilled water for 3 to 5 times, or soak it in 95% alcohol for 1 hour and then wipe it dry or dry it for later use. Draw blood from the tail of grass carp and drop the blood on one end of the spare slide about 4mm to 5mm. Use a pusher to evenly spread the blood on the slide to form a thin and uniform blood film. After the blood film is dry, fix it with anhydrous methanol for 3 minutes, then use Giemsa staining solution, stain at room temperature for 15 minutes, and finally rinse it slowly from one end of the slide with distilled water, and examine it under a microscope after drying.

[0046] The method for calculating the number of leukocytes of the present invention includes (generally counting 5 times in parallel and taking the average value):

[0047] WBC count = A / N × M1 × 10 × 106

[0048] In the formula, N is the number of squares observed under a microscope, and N in the present invention is 4; M1 is the magnification of the blood smear, and M1 in the present invention is 20; A is the total number of white blood cells in the N squares observed under a microscope.

[0049] The paraffin section preparation of the present invention comprises:

[0050] After collecting the liver, intestine and muscle tissues of grass carp, they were immediately fixed in Bonn's solution. After fixation for 20 hours, the tissues were transferred to alcohol solution for dehydration, and then embedded in paraffin, sectioned, stained with hematoxylin-eosin, and sealed with neutral gum. They were then observed and photographed under a microscope (Olympus BX51).

[0051] (I) Isolation and identification

[0052] 1.1 Isolation of strains:

[0053] 1.1.1 Isolation of Saprolegnia pathogens and antagonistic fungi strains:

[0054] From the breeding pond in Jingzhou, Hubei, a dying grass carp with wounds on its body surface was collected and recorded as grass carp A. Figure 1 Grass carp A had congestion around its eyes and at the base of its pelvic fins, and some scales had fallen off its body surface. Grass carp A was transported to the laboratory of the Yangtze Fisheries Research Institute, Chinese Academy of Fishery Sciences.

[0055] The body surface of grass carp A was sprayed with alcohol, the eyes of grass carp A were taken out, the lens was pierced with sterile tweezers, and the pierced lens was placed on potato dextrose agar medium and cultured at 25°C for 3 days. Mycelium grew on the potato dextrose agar medium.

[0056] Use a sterile scalpel to cut out a 5mmX5mm rectangular block covered with hyphae, and place the 5mmX5mm rectangular block covered with hyphae upside down on a new potato dextrose agar medium (with hyphae facing the potato dextrose agar medium), and culture it at 25°C for 3 days. Repeat this step until a single strain grows on the potato dextrose agar medium, and the white strain with hyphae is the Saprolegnia pathogen.

[0057] For the single yellowish strain on the potato dextrose agar medium (with an inhibition zone around the single yellowish strain), cut a 5mmX5mm yellowish rectangular block with a sterile scalpel, and place the 5mmX5mm yellowish rectangular block upside down on a new potato dextrose agar medium (with the yellowish strain facing the potato dextrose agar medium), and culture it at 25°C for 3 days. Until a single strain grows on the potato dextrose agar medium. Repeat this step until a single strain grows on the potato dextrose agar medium.

[0058] 1.1.2 Isolation of Lactobacillus:

[0059] Da Vinci pure yogurt (original flavor) produced by New Hope Dairy Co., Ltd. was diluted 10 times and 100 ul was evenly spread on the Lactobacillus delbrueckii culture medium. The culture medium plate was sealed to ensure airtightness and placed in a 37°C constant temperature incubator for 48 hours.

[0060] Pick out single colonies that are white or light yellow, have a sticky texture, are round, slightly raised, have neat edges, and conform to the typical morphology of lactobacillus, streak them on Lactobacillus delbrueckii culture medium, and culture them in a 37°C constant temperature incubator for 48 hours.

[0061] 1.2 Purification of Saprolegnia pathogens and antagonistic fungi

[0062] 1.2.1 Purification of Saprolegnia pathogens and antagonistic fungi strains

[0063] After typical colonies appear on the potato dextrose agar medium, pick the white single colonies with the colony characteristics of standard Saprolegnia, the colony characteristics of standard Epicoccumnigrum, and the yellow single colonies that produce inhibition zones (inhibit Saprolegnia pathogens) for reference. Figure 2 .

[0064] The two groups of selected single colonies were cultured three times in a row respectively. The colony morphology in the culture medium was consistent and the cell morphology of the strain was single, that is, the pure strain of the Saprolegnia pathogen and the pure strain of the antagonistic fungus were obtained.

[0065] 1.2.2 Purification of Lactobacillus

[0066] After typical colonies appear on the Lactobacillus delbrueckii culture medium, single colonies with colony characteristics of standard Lactobacillus are picked and cultured three times in succession. If the colony morphology in the culture medium is consistent and the cell morphology of the strain is single, a pure strain of Lactobacillus is obtained.

[0067] 1.3 Biological identification of strains:

[0068] 1.3.1 Biological identification of pathogenic bacteria and antagonistic fungal strains:

[0069] The specific method refers to the instructions of the fungal DNA extraction kit (Ezup column fungal genomic DNA extraction kit) to extract the DNA of the Saprolegnia pathogen and the antagonistic fungal strain respectively.

[0070] ITS rDNA analysis

[0071] The universal primers ITS1 and ITS4 of the fungal ITS region were used to identify pathogens and antagonistic fungal strains: Primer ITS1: 5'-TCCGTAGGTGAACCTGCGG-3'; Primer ITS4 (5'-TCCTCCGCTTATTGATATGC-3').

[0072] PCR reaction system: using the extracted genome as template, the total system is 50 μl: 25 μl ExTaq enzyme, 2 μl primer ITS1, 2 μl primer ITS4, 2 μl template, add double distilled water to make up to 50 μl.

[0073] PCR amplification conditions: pre-denaturation at 95°C for 3 min. Enter 35 cycles: denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for 1 min. Final extension at 72°C for 10 min. Terminate the reaction at 4°C.

[0074] After amplification, 5 μl of the PCR product was subjected to 1% agarose gel electrophoresis, and the amplified product was sent to Wuhan Tianyi Huiyuan Biotechnology Co., Ltd. for sequencing. The sequencing results were aligned using GenBank blast, and the phylogenetic tree was constructed using the neighbor-joining method using MEGA5.0 software.

[0075] Figure 3 M is the standard template, 1, 2, 3 and 4 are pathogenic bacteria, and 5 and 6 are antagonistic fungal strains. Figure 3 It can be seen that the length of the 16SrDNA sequence of the pathogen is 708bp, and the length of the 16SrDNA sequence of the antagonistic fungus strain is 527bp. Figure 4 The pathogen was grouped together with Saprolegnia ferax (Accession No.: GQ119935.1). Based on the morphological and molecular biological characteristics, the pathogen was identified as Saprolegnia ferax and named Saprolegnia ferax CY01. Figure 4 The antagonistic fungus strain has a homology of up to 100% with Epicoccumnigrum, and is clustered together with Epicoccumnigrum (accession number: OQ555113.1). Based on morphological and molecular biological characteristics, the antagonistic fungus strain was identified as Epicoccumnigrum and named Epicoccumnigrum Z01.

[0076] The nucleotide sequence of Escherichia cocci Z01 is as follows:

[0077] GGGTGACCTGCGGAAGGATCATTACCTAGAGTTTGTAGACTTCGGTCTGCTACCTCTT

[0078] ACCCATGTCTTTTGAGTACCTTCGTTTCCTCGGCGGGTCCGCCCGCCGATTGGACAAC

[0079] ATTCAAACCCTTTGCAGTTGCAATCAGCGTCTGAAAAAACATAATAGTTACAACTTTC

[0080] AACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTA

[0081] GTGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACATTGCGCCCCTTG

[0082] GTATTCCATGGGGCATGCCTGTTCGAGCGTCATTTGTACCTTCAAGCTCTGCTTGGTGT

[0083] TGGGTGTTTTGTCTCGCCTCTGCGTGTAGACTCGCCTTAAAACAATTGGCAGCCGGCG

[0084] TATTGATTTCGGAGCGCAGTACATCTCGCGCTTTGCACTCATAACGGCGACGTCCAAA

[0085] AGTACATTTTTACACTCTTGACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCAT

[0086] ATCT

[0087] The nucleotide sequence of *Saprolegnia ferax* CY01 is as follows:

[0088] GAAGGATCATTACCACACCAAAAAACACCCCACGTGAATGTACTCTTTATGAGGCTTG

[0089] CGCTGCCCTTGTGGCGGCTAGCCGAAGGTTTCGCAAGAAGCCGATGTCAATTTGAATC

[0090] CTTTTTAAACTACGACTGATCAAAACTGCAGATAGAAATGTCTGCATGCAATTGAAATA

[0091] CAACTTTCAACAGTGGATGTCTAGGCTCGCACACCGATGAAGAACGCTGCGAACTGC

[0092] GATACGTAATGCGAATTGCAGAATTCAGTGAGTCATCAAAATTTTGAACGCATATTGCA

[0093] CTTCCGGGTTAGTCCTGGGAGTATGTTTGTATCAGTGTCCGTGAACACAACCTTGTTTC

[0094] ATTTCTTGATTGAGATGGAGCAGAATGTGAAGGTCTTGTAATTACAAGTCCTTTTAAAC

[0095] GACGGTACCTATGCGTCCTCGTGAGATGTATTATTTAAAGGTATGCCTGCGCTTCTTTC

[0096] GAGAGTTTTGTGTGGCGGCACACAGCATTCAAAGAGAGAGCAAATCGCGGTAGTTTT

[0097] GCTTGTATTTCGGTACGAGTGGACACATATTGCTTTTTGTGATTTCTGCGAGTCTGTTG

[0098] TTTAAGCACAGGACACGTAAGGAGAGTGAGTATGCTGGTGCATTTCTTGGCGCATGGA

[0099] GGCAAATTGGGAATTCAATCCAATTTGGACCTGATATCAAACAAGACTACCCGCTGAA

[0100] CTTAAGCA

[0101] 1.3.2 Biological identification of Lactobacillus:

[0102] The DNA of lactobacillus was extracted according to the instructions of a bacterial DNA extraction kit (Bacterial Genomic DNA Extraction Kit (DP302)) for bacterial DNA extraction.

[0103] Specifically, the purified single lactobacillus colony is used as a template and amplified using universal primers for 16SrRNA sequencing, for example, the commonly used primer pair 1492r / F27. The sequence of the forward primer 27F is 5'-TACGGYTACCTTGTTACGACTT-3'; the sequence of the reverse primer 1492R is 5'-AGAGTTTGATCMTGGCTCAG-3'.

[0104] PCR reaction system: Using the extracted genome as template, the total PCR reaction system is 50 μl: 25 μl Taq DNA polymerase, 1 μl forward primer, 1 μl reverse primer, 2 μl template, and double distilled water is added to make up to 50 μl.

[0105] PCR conditions: pre-denaturation at 95°C for 5 min. Then 35 cycles were performed: denaturation at 95°C for 30 s; annealing at 55°C for 45 s, extension at 72°C for 1 min 20 s. Extension at 72°C for 15 min; termination at 4°C.

[0106] After the amplification, 5 μl of the amplified product was verified by 1% agarose gel, sequenced by Wuhan Tianyi Huiyuan Biotechnology Co., Ltd., and blast sequence comparison was performed at NCBI to determine that the isolated lactobacillus was Lactobacillus paracasei, named Lactobacillus paracasei LY02.

[0107] The nucleotide sequence of Lactobacillus paracasei LY02 is as follows:

[0108] TGCAAGTCGAACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAACATGGAA

[0109] CGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACA

[0110] TTTGGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGAAA

[0111] GATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGT

[0112] AATGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTG

[0113] GGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAAT

[0114] GGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAA

[0115] AACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTAT

[0116] CCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGC

[0117] AAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGAT

[0118] GTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGC

[0119] AGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAA

[0120] CACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATG

[0121] GGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGT

[0122] GTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGG

[0123] AGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTG

[0124] GAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTT

[0125] GATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGT

[0126] TGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTA

[0127] TGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGA

[0128] GGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGC

[0129] TACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCC

[0130] ATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAA

[0131] TCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCA

[0132] CACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTAGGGAGCGAGC

[0133] C

[0134] (II) Preparation of Saprolegnia inhibitors

[0135] 2.1 Saprolegnia Inhibitor A

[0136] Saprolegnia inhibitor A: includes Agaricus bisporus polysaccharide and culture solution of Echinococcus nigromatus Z01. The OD600 of the culture solution of Echinococcus nigromatus Z01 is 1.2-1.5, and the concentration of Agaricus bisporus polysaccharide is 100-500 mg / L. In a specific embodiment of the present invention, the concentration of Agaricus bisporus polysaccharide is 300 mg / L.

[0137] When used, the primary black cloacae Z01 purified in 1.2 is inoculated into 200 mL of potato dextrose broth medium and cultured in a shaker at 175 rpm and 25° C. for 5 days. After filtering through 3 layers of sterile gauze, a black cloacae Z01 culture solution is obtained, and the OD600 of the black cloacae Z01 culture solution is 1.2-1.5. In a specific embodiment of the present invention, the OD600 of the black cloacae Z01 culture solution is 1.3.

[0138] In practical application, 1-5 mg of Agaricus bisporus polysaccharide is mixed with 10 mL of Nigrococcus Z01 culture solution, and stirred evenly to obtain Saprolegnia inhibitor A. In a specific embodiment of the present invention, 3.0 mg of Agaricus bisporus polysaccharide is mixed with 10 mL of Nigrococcus Z01 culture solution, and stirred evenly to obtain Saprolegnia inhibitor A.

[0139] 2.2 Saprolegnia Inhibitor B

[0140] Saprolegnia inhibitor B: includes Agaricus bisporus polysaccharide, Echinococcus nigrosin Z01 culture solution, and Lactobacillus paracasei LY02 culture solution. The OD600 of the Lactobacillus paracasei LY02 culture solution is 1.2-1.5. In a specific embodiment of the present invention, the OD600 of the Lactobacillus paracasei LY02 culture solution is 1.4.

[0141] During application, Lactobacillus paracasei LY02 is inoculated in 200 ml of Lactobacillus delbrueckii liquid culture medium, and is placed in a shaking table at 175 rpm and 25 ℃ and cultivated for 5 days. Then, the culture fluid of Lactobacillus paracasei LY02 is obtained by filtering with three layers of sterilized gauze. The OD of the culture fluid of Lactobacillus paracasei LY02 is 1.2-1.5. In a specific embodiment of the present invention, the OD600 of the culture fluid of Lactobacillus paracasei LY02 is 1.4.

[0142] In practical application, 1-5 mg of Agaricus bisporus polysaccharide, 10 mL of Nigrococcus Z01 culture solution, and 10 ml of Lactobacillus paracasei LY02 culture solution are mixed and stirred evenly to obtain Saprolegnia inhibitor B. In a specific embodiment of the present invention, 3.0 mg of Agaricus bisporus polysaccharide, 10 mL of Nigrococcus Z01 culture solution, and 10 ml of Lactobacillus paracasei LY02 culture solution are mixed and stirred evenly to obtain Saprolegnia inhibitor B.

[0143] 3.3 Saprolegnia Inhibitor C

[0144] Saprolegnia inhibitor C: includes Agaricus bisporus polysaccharide, Echinococcus nigromatis Z01 culture solution, Lactobacillus paracasei LY02 culture solution, and ergothioneine. The concentration of ergothioneine is 300-500 μmol / L. In a specific embodiment of the present invention, the concentration of ergothioneine is 400 μmol / L.

[0145] When used, 1-5 mg of Agaricus bisporus polysaccharide, 3-5 μmol ergothioneine, 10 ml of nigrococcus Z01 culture solution, and 10 ml of Lactobacillus paracasei LY02 culture solution are mixed and stirred evenly to obtain Saprolegnia inhibitor C. In a specific embodiment of the present invention, 3.0 mg of Agaricus bisporus polysaccharide, 4 μmol ergothioneine, 10 ml of nigrococcus Z01 culture solution, and 10 ml of Lactobacillus paracasei LY02 culture solution are mixed and stirred evenly to obtain Saprolegnia inhibitor C.

[0146] (III) Application of Saprolegnia inhibitors

[0147] Grass carp weighing 70-100 g were kept for 14 days and then divided into blank control group, infection group, Agaricus bisporus polysaccharide group, ergothioneine group, Lactobacillus group, Z01 group, Saprolegnia inhibitor A group, Saprolegnia inhibitor B group, and Saprolegnia inhibitor C group.

[0148] Blank control group: aerated aquaculture water was added to the aquaculture water body, and the water temperature was maintained at 18°C.

[0149] Infection group: Aerated aquaculture water was added to the aquaculture water body, and the water temperature was maintained at 18°C.

[0150] Agaricus bisporus polysaccharide group: Agaricus bisporus polysaccharide was added to the culture water, the final concentration of Agaricus bisporus polysaccharide was 300 mg / L, and the water temperature was maintained at 18°C. Soak for 1 hour each time, and soak for 3 consecutive days. At the same time, Agaricus bisporus polysaccharide was stirred into the fish bait, and the concentration of Agaricus bisporus polysaccharide in the fish bait was 300 mg / kg. Feed once a day for 3 consecutive days.

[0151] Ergothioneine group: Add ergothioneine to the aquaculture water, the final concentration of ergothioneine is 400μmol / L, and the water temperature is maintained at 18℃. Soak for 1h each time, and soak for 3 days. At the same time, stir ergothioneine into the bait, the concentration of ergothioneine in the bait is 400μmol / kg. Feed once a day for 3 days.

[0152] Lactobacillus group: Lactobacillus paracasei LY02 culture solution was added to the aquaculture water, and the final concentration of Lactobacillus paracasei LY02 was 1.0-5.0×10 9 CFU / mL (In a specific embodiment of the present invention, the final concentration of Lactobacillus paracasei LY02 is 3.0×10 9 CFU / mL), and the water temperature was maintained at 18°C. Each soaking was for 1 hour, and the soaking was continued for 3 days. At the same time, the culture solution of Lactobacillus paracasei LY02 was stirred into the bait, and the concentration of Lactobacillus paracasei LY02 in the bait was 1.0-5.0×10 9 CFU / g (In a specific embodiment of the present invention, the concentration of Lactobacillus paracasei LY02 in the bait is 3.0×10 9CFU / g). Once a day, for 3 consecutive days.

[0153] Group Z01: The culture medium of Echinococcus nigromaculata Z01 was added to the aquaculture water. The final concentration of Echinococcus nigromaculata Z01 spores was 2.0×10 8 Z01 spores / ml, and the water temperature was maintained at 18°C. Soak for 1 hour each time, and soak for 3 days continuously. At the same time, stir the culture solution of Nigrococcus Z01 into the bait, and the concentration of Nigrococcus Z01 spores in the bait is 2.0×10 8 . Feed once a day for 3 consecutive days.

[0154] Saprolegnia inhibitor A group: Saprolegnia inhibitor A was added to the aquaculture water, the final concentration of Agaricus bisporus polysaccharide was 300 mg / L, and the final concentration of Echinococcus nigromaculata Z01 spores was 2.0×10 8 Z01 spores / ml, and the water temperature was maintained at 18℃. Each soaking was for 1 hour, and the soaking was continued for 3 days. At the same time, Saprolegnia inhibitor A was stirred into the bait. The concentration of Agaricus bisporus polysaccharide in the bait was 300mg / kg, and the concentration of Echinococcus nigrosporus Z01 spores was 2.0×10 8 . Feed once a day for 3 consecutive days.

[0155] Saprolegnia inhibitor B group: Saprolegnia inhibitor B was added to the aquaculture water, the final concentration of Agaricus bisporus polysaccharide was 300 mg / L, and the final concentration of Lactobacillus paracasei LY02 was 3.0×10 9 CFU / mL, the final concentration of E. nigrosinophilus Z01 spores was 2.0×10 8 Z01 spores / ml, and the water temperature was maintained at 18℃. Soak for 1 hour each time for 3 consecutive days. At the same time, stir the Saprolegnia inhibitor B into the bait, the concentration of Agaricus bisporus polysaccharide in the bait was 300mg / kg, and the concentration of Echinococcus nigrosporus Z01 spores was 2.0×10 8 The final concentration of Lactobacillus paracasei LY02 was 3.0×10 9 CFU / g. Once a day, for 3 consecutive days.

[0156] Saprolegnia inhibitor C group: Saprolegnia inhibitor C was added to the aquaculture water, the final concentration of Agaricus bisporus polysaccharide was 300 mg / L, and the final concentration of Lactobacillus paracasei LY02 was 3.0×10 9 CFU / mL, the final concentration of E. nigrosinophilus Z01 spores was 2.0×10 8 Z01 spores / ml, the final concentration of ergothioneine was 400 μmol / L, and the water temperature was maintained at 18°C. At the same time, Saprolegnia inhibitor B was stirred into the bait, the concentration of Agaricus bisporus polysaccharide in the bait was 300 mg / kg, the concentration of Echinococcus nigromaculata Z01 spores was 2.0×10 8 The final concentration of Lactobacillus paracasei LY02 was 3.0×10 9CFU / g, the final concentration of ergothioneine was 400 μmol / kg. Feed once a day for 3 consecutive days.

[0157] When used, the bait is an expanded compound feed without any drug additives. The expanded compound feed is produced by Jiangmen Xinjian Feed Co., Ltd., and the product ingredients are as follows: crude protein ≥ 32%, crude fiber ≤ 15%, crude fat ≥ 3.5%, crude ash ≤ 15%, total phosphorus ≥ 0.5%, moisture ≤ 12%, and lysine ≥ 1.4%.

[0158] After the grass carp were soaked and fed with saprolegnia inhibitors, wounds of equal size were artificially made on the same part of each grass carp in the infection group, Agaricus bisporus polysaccharide group, ergothioneine group, Lactobacillus group, Z01 group, Saprolegnia inhibitor A group, Saprolegnia inhibitor B group, and Saprolegnia inhibitor C group, and infected with Saprolegnia multifida CY01 (for details, refer to the method of infecting Saprolegnia recorded in the paper "Construction and Application of Saprolegnia Disease Model in Fishes" published by Xu Jialu in the Journal of Shanghai Ocean University in 2012). Then, the grass carp were observed for 7 consecutive days, and the infection rate, changes in the number of red blood cells, changes in the number of white blood cells, changes in hemoglobin, changes in blood cells, and changes in tissues were recorded.

[0159] refer to Figure 1 It can be seen that when the fish body has no wounds, even if there are saprolegnia pathogens in the breeding water, grass carp fluid is difficult to be infected with saprolegnia; when the fish body has wounds and there are saprolegnia pathogens in the water, grass carp is easily infected with saprolegnia. Specifically, the infection rate of the blank control group is 0, and the infection group is 100% infected. It can be seen that the experimental environment meets the conditions for saprolegnia infection and the experimental design is successful. Further, the infection rate of the Agaricus bisporus polysaccharide group is 90%, and the infection rate of the ergothioneine group is 80%, which is likely to be due to the increase of nutrients in the breeding water, which improves the resistance of grass carp. The infection rates of the Lactobacillus group and the Z01 group decreased significantly. It can be seen that both Lactobacillus paracasei LY02 and Black Coccus Z01 can inhibit the activity of Saprolegnia multifida CY01, and the inhibitory effect of Black Coccus Z01 is significantly better than that of Lactobacillus paracasei LY02. After combination, the infection rate of the Saprolegnia inhibitor C group is only 10%, which shows that the Saprolegnia inhibitor C group can effectively inhibit the infection of Saprolegnia multifida CY01 to injured fish.

[0160] Referring to Table 1, it can be seen that compared with the blank control group, the changes in the content of white blood cells, red blood cells and hemoglobin of grass carp in the infection group, Agaricus bisporus polysaccharide group, ergothioneine group, lactobacillus group, Z01 group, Saprolegnia inhibitor A group, Saprolegnia inhibitor B group and Saprolegnia inhibitor C group did not reach a statistically significant level, which shows that Saprolegnia infection generally does not cause bacterial infection in the early stage. Further, from the changes in the content of white blood cells, red blood cells and hemoglobin in each group, the drug components of the Saprolegnia inhibitors in each group will not cause significant changes in white blood cells, red blood cells and hemoglobin, indicating that it is safe for grass carp.

[0161] Table 1 Changes in red blood cells, white blood cells and hemoglobin of grass carp

[0162] Group <![CDATA[Red blood cell count × 10 12 / L]]> <![CDATA[White blood cell count × 10 10 / L]]> Hemoglobin × g / L Blank control group 2.29±0.19a 4.43±0.47a 75.13±4.37a Infection group 2.38±0.24a 4.26±0.53a 74.77±3.34a Agaricus bisporus polysaccharide group 2.51±0.22a 4.25±0.42a 73.74±3.62a Ergothioneine group 2.55±0.24a 4.28±0.41a 72.44±2.91a Lactobacillus group 2.19±0.19a 4.93±0.47a 72.03±4.37a Z01 Group 2.88±0.24a 4.26±0.53a 71.77±3.34a Saprolegnia Inhibitor Group A 2.21±0.22a 4.15±0.42a 73.74±3.62a Saprolegnia Inhibitor Group B 2.35±0.24a 4.28±0.41a 72.44±2.91a Saprolegnia Inhibitor Group C 2.25±0.25a 4.78±0.42a 77.44±2.92a

[0163] Figure 2-Figure 4 In the figure, a is the blank control group; b is the infection group; c is the Agaricus bisporus polysaccharide group; d is the ergothioneine group; e is the Lactobacillus group; f is the Z01 group; g is the Saprolegnia inhibitor A group; h is the Saprolegnia inhibitor B group; i is the Saprolegnia inhibitor C group.

[0164] refer to Figure 2 It can be seen that there is no obvious abnormality in the liver tissue sections of grass carp in each group. The liver cells of the liver tissue are arranged in double rows in a plate-like shape. The liver plates are scattered around the central vein, and the liver cells are irregular polygons.

[0165] Figure 2 In a: The hepatocytes in the liver tissue are arranged in plates, and the liver plates are scattered around the central vein. The hepatocytes are irregular polygons with large and round nuclei. The adjacent hepatocyte cords are irregular and interconnected to form a network of hepatic sinusoids, and there is no obvious expansion of the hepatic sinusoids. There is no obvious abnormality in the tissue. Figure 2 In b: In the liver tissue, the central vein is surrounded by hepatocytes and hepatic sinusoids arranged roughly radially, with diffuse hepatocyte hydropic degeneration and loose and lightly stained cytoplasm; the hepatic plates are arranged regularly and neatly, and there is no obvious expansion or compression of the hepatic sinusoids; there is no obvious abnormality in the portal area between adjacent hepatic lobules; no obvious inflammatory changes are observed. Figure 2 In c: The hepatocytes in the liver tissue are arranged in two rows in plate-like shape. The hepatic plates are scattered around the central vein. The hepatocytes are irregular polygons with little cytoplasm and are vacuolated. The adjacent hepatocyte cords are irregular and interconnected to form a network of hepatic sinusoids. There is no obvious expansion of the hepatic sinusoids. There is no obvious inflammatory cell infiltration. Figure 2 In d: The hepatocytes in the liver tissue are arranged in double rows in plate-like shape. The hepatic plates are scattered around the central vein, and the hepatocytes are irregular polygons. Compared with the blank control, the cytoplasm content of the hepatocytes increased slightly, and no other significant differences were observed. Figure 2In e: The hepatocytes in the liver tissue are arranged in double rows in plate-like shape. The hepatic plates are scattered around the central vein, and the hepatocytes are irregular polygons. Compared with the blank control, the cytoplasm content of the hepatocytes increased slightly, and no other significant differences were observed. Figure 2 In f, the hepatocytes in the liver tissue were arranged in double rows in plate-like shape. The hepatocytes were scattered around the central vein. The hepatocytes were irregular polygons with little cytoplasm and were vacuolated. Compared with the blank control, a small amount of lymphocyte infiltration was seen around the local blood vessels. No other significant differences were observed. Figure 2 In the g, a large number of hepatocyte cytoplasm vacuoles were observed in the liver tissue; venous congestion was rare; and no obvious inflammatory cell infiltration was observed. Figure 2 In h: A large number of hepatocyte cytoplasm vacuoles can be seen in the liver tissue; no obvious inflammatory cell infiltration is observed. Figure 2 In the i: the hepatocytes are arranged in two rows in plate shape, the hepatic plates are scattered around the central vein, the hepatocytes are irregular polygons, and the cell nuclei are large and round; the adjacent hepatocyte cords are irregular and interconnected to form a network of hepatic sinusoids, and the hepatic sinusoids have not been significantly dilated; there is no obvious abnormality in the tissue.

[0166] refer to Figure 3 It can be seen that there was no obvious abnormality in the intestinal sections of grass carp in each group. The structures of each layer of intestinal tissue were clear, the number of intestinal villi in the mucosal layer was abundant, the mucosal epithelium was intact, the cells were arranged regularly, the surface was a single layer of columnar epithelium, the morphology and structure were normal and arranged neatly, there were goblet cells distributed between the epithelial cells, and the muscular layer and serosal layer composed of smooth muscle cells were visible under the intestinal wall.

[0167] Figure 3 The structures of each layer of intestinal tissue are clear, the number of intestinal villi in the mucosal layer is abundant, the mucosal epithelium is intact, the cells are arranged regularly, and occasionally the epithelium at the top of the intestinal villi is separated from the propria layer; the muscle cells in the muscular layer are arranged regularly and have normal morphology; no obvious inflammatory changes are observed. Figure 3 The structures of each layer of intestinal tissue in b were clear, the number of intestinal villi in the mucosal layer was abundant, and the mucosal epithelium was intact. Compared with the blank control, the connective tissue in the lamina propria proliferated with edema, the connective tissue was loosely arranged, and there was a small amount of lymphocyte infiltration. No other significant differences were found. Figure 3 The structures of each layer of intestinal tissue in c were clear, and the number of intestinal villi in the mucosal layer was abundant. Compared with the blank control, the mucosal epithelium was partially missing, the intestinal villus epithelium was rarely separated from the lamina propria, the connective tissue of the lamina propria proliferated with edema, the connective tissue was loosely arranged, and there was a small amount of lymphocyte infiltration. No other significant differences were found. Figure 3 The intestinal tissue layers of the d were clearly structured, the intestinal villi in the mucosal layer were abundant, and the mucosal epithelium was intact; compared with the blank control, the intestinal villus epithelium was often separated from the propria layer, and no other significant differences were observed. Figure 3A small amount of epithelial cell shedding was observed in the mucosal layer of the intestinal tissue; no obvious abnormality was observed in the lamina propria, the muscularis was evenly stained, the muscle fibers had normal morphology and structure and were arranged regularly, and no obvious inflammatory cell infiltration was observed. Figure 3 The intestinal mucosal layer had abundant villi and goblet cells, with rare necrosis and shedding of epithelial cells at the top of the villi, and condensed, darkly stained and fragmented nuclei. There was no obvious hyperplasia and inflammatory cell infiltration. Figure 3 The surface of the small intestine is distributed with intestinal villi, which are abundant in number. The surface is a single-layer columnar epithelium with normal morphology and structure and neat arrangement. Goblet cells are distributed between the epithelial cells. The muscular layer and serosa layer composed of smooth muscle cells can be seen under the intestinal wall, and no obvious abnormalities are observed. Figure 3 The structures of each layer of intestinal tissue are clear. The intestinal villus epithelium is a single-layer columnar epithelium with densely arranged cells. There are a large number of goblet cells with a slightly reduced size. Most of them are arranged in 2-3 rows on the mucosal surface and locally aggregated into clusters. The intestinal villi are abundant, most of which are finger-shaped, cone-shaped and tooth-shaped, arranged regularly, and have no intestinal glands. The muscle layer is relatively thick, and the morphology and structure of muscle fibers are normal. No obvious inflammatory cell infiltration was observed.

[0168] refer to Figure 4 It can be seen that there is no obvious difference in the muscle tissue sections of each group of grass carp. The muscle cells in the muscle tissue are arranged regularly, colored evenly, have clear boundaries, and the nuclei are located at the edges. Several muscle cells are gathered into bundles. Each muscle bundle is wrapped by a perimysium composed of loose connective tissue, and there is no obvious abnormality in the tissue.

[0169] Figure 4 In the muscle tissues of a, b, c, d, e, and f, the muscle cells are arranged regularly, colored evenly, and have clear boundaries. The nuclei are located at the edges, and several muscle cells are gathered into bundles. Each muscle bundle is wrapped by a perimysium composed of loose connective tissue, and no obvious abnormalities are observed in the tissues. Compared with the blank control, no significant differences were observed. Figure 4 The muscle tissue in g, h, and i was stained evenly, and the muscle fibers had normal morphology and structure, clear boundaries, and regular arrangement. There was no obvious abnormality in the interstitium, and no obvious inflammatory cell infiltration was observed.

[0170] In summary, the saprolegnia inhibitor of the present invention can effectively inhibit the vitality and reproductive capacity of fungi, and in particular can prevent saprolegniasis caused by saprolegnia pathogenic bacteria. It can be seen that the present invention not only enriches the types of biocontrol bacteria, but also broadens the application of biocontrol bacteria in the field of saprolegniasis prevention and control in aquaculture. The present invention not only provides a new solution for the prevention and control of saprolegniasis in freshwater aquaculture animals, but also effectively avoids the problem of drug residues.

[0171] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, substitute and modify the above embodiments within the scope of the invention without departing from the principles and purpose of the present invention. All such changes should fall within the scope of protection of the claims of the present invention.

Claims

1. A Saprolegnia inhibitor, characterized in that include: Agaricus bisporus polysaccharide and Epicoccumnigrum Z01; The deposit number of Echinococcus nigromaculata Z01 is CCTCCNO: M2024967.

2. The Saprolegnia inhibitor according to claim 1, characterized in that The concentration of Agaricus bisporus polysaccharide in the saprolegnia inhibitor is 100-500 mg / L, and the spore concentration of Echinococcus nigrospermum Z01 is 1.0-8.0×10 8 Pieces / mL.

3. The Saprolegnia inhibitor according to claim 1, characterized in that Also includes: Lactobacillus paracasei LY02, wherein the concentration of Lactobacillus paracasei LY02 in the saprolegnia inhibitor is 1.0-5.0×10 9 CFU / mL.

4. The Saprolegnia inhibitor according to claim 1, characterized in that Also includes: Ergothioneine, wherein the concentration of ergothioneine in the saprolegnia inhibitor is 300-500 μmol / L.

5. A method for preparing a saprolegnia inhibitor, characterized in that: The following steps are involved: The black Escherichia coccus Z01 was inoculated into a potato dextrose broth medium and cultured in a shaking incubator, and the black Escherichia coccus Z01 culture fluid was obtained after filtering through three layers of sterile gauze; Agaricus bisporus polysaccharide is added into the culture solution of Echinococcus nigrosporus Z01, and the mixture is evenly mixed to obtain a Saprolegnia inhibitor.

6. The method for preparing the saprolegnia inhibitor according to claim 5, characterized in that: Also includes: Inoculating Lactobacillus paracasei LY02 into a Lactobacillus delbrueckii liquid culture medium, and culturing the medium in a shaking table, filtering the medium through three layers of sterile gauze to obtain a Lactobacillus paracasei LY02 culture medium; The culture solution of Lactobacillus paracasei LY02 was added to the culture solution of Echinococcus nigromatis Z01, and the mixture was evenly mixed to obtain a Saprolegnia inhibitor.

7. The method for preparing the saprolegnia inhibitor according to claim 5, characterized in that: Also includes: Ergothioneine is added into the culture solution of Echinococcus nigromaculata Z01, and the mixture is evenly mixed to obtain a Saprolegnia inhibitor.

8. The method for preparing the saprolegnia inhibitor according to claim 5, characterized in that: The OD600 of the culture solution of Echinococcus nigromaculata Z01 is 1.2-1.

5.

9. The method for preparing the saprolegnia inhibitor according to claim 6, characterized in that: The OD600 of the Lactobacillus paracasei LY02 culture solution is 1.2-1.

5.

10. Use of a Saprolegnia inhibitor in treating or preventing fungal infection, wherein the Saprolegnia inhibitor is the Saprolegnia inhibitor according to any one of claims 1 to 4.

Citation Information

Patent Citations

  • Fungicidal mixtures

    CN102595903A

  • Compound bacterial agent containing bacillus methylotrophicus and application thereof in preparation of drugs for aquatic animal diseases

    CN110468071A

  • The method for enhancing sporulation and producing mass spore of spore-forming fungi including epicoccosorus nematosporus

    KR100770366B1

  • Inhibiting or reducing fungal growth

    US20160021890A1